Detect liver cancer earlier than ever before.
HelioLiver LDT is a groundbreaking blood test that has shown to be 4x more effective* than the current standard (ultrasound) at detecting Stage I hepatocellular carcinoma (HCC), the most common type of liver cancer.
*As shown in the prospective CLiMB trial looking at high risk cirrhotic patients.
Innovative technology with higher sensitivity makes early detection possible
By combining the results of cell-free DNA methylation testing with data from protein tumor markers and other clinical information, HelioLiver LDT delivers superior performance characteristics when compared to traditional tests for hepatocellular carcinoma (HCC).
Higher sensitivity to detecting smaller cancerous tumors means catching liver cancer cases in early stages, when curative options are available.
HELIOLIVER VS. ULTRASOUND
T1 HCC detection
44%
11%
HELIOLIVER
ULTRASOUND
Success in Detecting Cancerous Tumors As Observed In The CLiMB Trial
HELIOLIVER
ULTRASOUND
29%
0%
TUMOR SIZE: ≤ 2 CM
Potential treament options:
Resection or transplant
12x Higher Survival for Early-Stage Liver Cancer...
But Less than 50% are diagnosed early enough.
Timing matters. Early detection can lead to better outcomes.
Fewer than half of all liver cancers in the US are diagnosed at an early stage while the disease is still localized. Early detection of liver cancer significantly improves outcomes for patients, allowing for a higher survival rate, and it opens up the door for potentially curative treatment options, such as surgery and transplant.
5-Year Relative Survival Rates from SEER Database
37%
3%
LOCALIZED (EARLY STAGE)
DISTANT (ADVANCED STAGE)
A Simple Blood Test for Liver Cancer
Introducing the HelioLiver LDT
HelioLiver reimagines how we find and fight liver cancer by simplifying testing for you and your patients. Now, you can efficiently test more patients with one simple, affordable blood test that integrates seamlessly with in-office patient care.
HelioLiver is now available as a laboratory-developed test (LDT).
Almost 90% of liver cancer is made up of hepatocellular carcinoma (HCC). Patients at risk for HCC, such as those with pre-existing cirrhosis are recommended for testing every 6 months.
Primary Risk for HCC
Cirrhosis
Major Causes of Cirrhosis
- Chronic hepatitis B (HBV)
- Chronic hepatitis C (HCV)
- Excessive alcohol use
- Nonalcoholic fatty liver disease (NAFLD)
This test was developed and its performance characteristics were determined by Helio Genomics. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). As an LDT, this test is regulated under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, which ensures quality laboratory testing. This test is intended for clinical purposes and should not be regarded as investigational or for research use only.
HelioLiver: Easy for patients, effortless for providers
Ordering the HelioLiver test is simple and straightforward
Our dedicated HelioLiver team is available to support any ordering, technical, and billing questions you may have. Our onboarding team will set you up with our ordering process and your very first set of HelioLiver Collection Kits.
Take the first step toward early detection and better outcomes. Order HelioLiver LDT today for a simple, reliable solution in liver cancer testing.
Order Now